Roth Capital initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Buy rating and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE